Maturing of Renal Cancer Therapeutics

被引：5

作者：

Stadler, Walter M. ^{[1
]}

机构：

[1] Univ Chicago, Chicago, IL 60637 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 08期

关键词：

PHASE-III TRIAL; INTERFERON-ALPHA; SUNITINIB; TEMSIROLIMUS; THERAPY; BEVACIZUMAB; RESISTANCE; SORAFENIB;

D O I：

10.1200/JCO.2013.54.1748

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：722 / 724

页数：3

共 18 条

[1]

[Anonymous], J UROL

[2] Oncology's trials [J].

Booth, B ;

Glassman, R ;

Ma, P .

NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (08) :609-610

[3] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[4] Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer [J].

Gan, Hui K. ;

You, Benoit ;

Pond, Gregory R. ;

Chen, Eric X. .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (08) :590-598

[5]

Halabi S, CANCER

[6] Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study [J].

Hammers, Hans J. ;

Verheul, Henk M. ;

Salumbides, Brenda ;

Sharma, Rajni ;

Rudek, Michelle ;

Jaspers, Janneke ;

Shah, Preeti ;

Ellis, Leigh ;

Shen, Li ;

Paesante, Silvia ;

Dykema, Karl ;

Furge, Kyle ;

Teh, Bin T. ;

Netto, George ;

Pili, Roberto .

MOLECULAR CANCER THERAPEUTICS, 2010, 9 (06) :1525-1535

[7]

Hodi FS, 2013, J CLIN ONCOL, V31

[8] Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma [J].

Huang, Dan ;

Ding, Yan ;

Zhou, Ming ;

Rini, Brian I. ;

Petillo, David ;

Qian, Chao-Nan ;

Kahnoski, Richard ;

Futreal, P. Andrew ;

Furge, Kyle A. ;

Teh, Bin Tean .

CANCER RESEARCH, 2010, 70 (03) :1063-1071

[9] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].

Hudes, Gary ;

Carducci, Michael ;

Tomczak, Piotr ;

Dutcher, Janice ;

Figlin, Robert ;

Kapoor, Anil ;

Staroslawska, Elzbieta ;

Sosman, Jeffrey ;

McDermott, David ;

Bodrogi, Istvan ;

Kovacevic, Zoran ;

Lesovoy, Vladimir ;

Schmidt-Wolf, Ingo G. H. ;

Barbarash, Olga ;

Gokmen, Erhan ;

O'Toole, Timothy ;

Lustgarten, Stephanie ;

Moore, Laurence ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281

[10] Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma [J].

Hutson, Thomas E. ;

Escudier, Bernard ;

Esteban, Emilio ;

Bjarnason, Georg A. ;

Lim, Ho Yeong ;

Pittman, Kenneth B. ;

Senico, Peggy ;

Niethammer, Andreas ;

Lu, Dongrui Ray ;

Hariharan, Subramanian ;

Motzer, Robert J. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (08) :760-+

← 1 2 →